Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NeurAxis, Inc. ( (NRXS) ) has provided an update.
On August 29, 2025, Neuraxis, Inc. entered into an At The Market Offering Agreement with Craig-Hallum Capital Group LLC, allowing the company to sell shares of its common stock worth up to $3.3 million. This strategic move aims to provide Neuraxis with financial flexibility and potentially strengthen its market position, as the sales agent will sell the stock based on the company’s instructions, with a commission of 3% on the gross sales proceeds.
The most recent analyst rating on (NRXS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on NeurAxis, Inc. stock, see the NRXS Stock Forecast page.
Spark’s Take on NRXS Stock
According to Spark, TipRanks’ AI Analyst, NRXS is a Neutral.
NeurAxis faces significant financial challenges with negative equity and cash flow issues, which heavily impact its overall score. Despite strong revenue growth and strategic milestones, ongoing losses and valuation concerns weigh down the stock’s attractiveness.
To see Spark’s full report on NRXS stock, click here.
More about NeurAxis, Inc.
Neuraxis, Inc. operates in the biotechnology industry, focusing on the development and commercialization of innovative medical solutions.
Average Trading Volume: 92,532
Technical Sentiment Signal: Buy
Current Market Cap: $25.04M
For detailed information about NRXS stock, go to TipRanks’ Stock Analysis page.